Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Electrum Advances AMT Geophysical Survey Identifying Additional Drill Targets (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Xeris Biopharma Holdings Inc XERS

Healthcare Biotechnology
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:XERS)

Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue

Business Wire January 8, 2026

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire January 2, 2026

Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application

Business Wire December 1, 2025

Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025

Business Wire November 6, 2025

Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025

Business Wire October 23, 2025

Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 3, 2025

Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®

Business Wire August 25, 2025

Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

Business Wire August 7, 2025

Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025

Business Wire July 31, 2025
View More News ››

Opinion & Analysis (NDAQ:XERS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:XERS)

Xeris Biopharma (XERS) Delivers Impressive Q1 2024 Results,

http://beyondspx.com/2024/08/02/xeris-biopharma-xers-delivers-impressive-q1-2024-results-raises-full-year-guidance/
MikeTester - August 3, 2024

GOING UP and NO ONE HERE

sh NOOBs are still fretting away on FAILED stock promos lol lol
WakeUPP - June 25, 2021
View more Bullboard ››

Mirasol Resources Ltd.

Mirasol Resources Ltd.

Mirasol Resources Ltd. engages in the acquisition and exploration of mineral properties in Chile and Argentina. The company ...
View More »

Podcasts